文献速递胸部肿瘤

基于二代测序分子谱的原发灶特异性及靶向治疗用于原发灶不明肿瘤:非随机2期临床试验

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究为日本19家机构开展的2期试验,纳入111例初治的不利亚型原发灶不明肿瘤患者,97例可评估疗效。根据RNA/DNA测序预测肿瘤起源并给予位点特异性治疗(含靶向治疗),1年生存概率53.1%,中位OS 13.7个月,中位PFS 5.2个月。

要点

  • NGS预测起源后给予位点特异性治疗,1年生存概率53.1%。
  • 中位OS 13.7个月,中位PFS 5.2个月。
  • 5例预测为非小细胞肺癌者检出可靶向EGFR突变,4例接受阿法替尼。

核心结论

  • 基于NGS基因表达和基因改变谱的位点特异性治疗(包括分子靶向治疗)可能有助于不利亚型原发灶不明肿瘤患者的治疗。

研究设计与样本

  • 日本19家机构开展的非随机2期临床试验,2015年3月至2018年1月纳入111例初治的不利亚型原发灶不明肿瘤患者,97例纳入疗效分析。

主要发现

  • 97例中女性49例(50.5%),中位年龄64岁(范围21-81岁)。
  • 预测最常见的肿瘤类型为肺癌21例(21%)、肝癌15例(15%)、肾癌15例(15%)、结直肠癌12例(12%)。
  • 最常见基因改变为TP53 45例(46.4%)、KRAS 19例(19.6%)、CDKN2A 18例(18.6%)。
  • 1年生存概率53.1%(95%CI 42.6%-62.5%),中位OS 13.7个月(95%CI 9.3-19.7个月),中位PFS 5.2个月(95%CI 3.3-7.1个月)。
  • 5例预测为非小细胞肺癌的患者检出可靶向EGFR突变(5.2%),其中4例接受阿法替尼治疗,2例获得超过6个月的持久PFS。

临床怎么用

  • 对不利亚型原发灶不明肿瘤患者,可考虑基于NGS基因表达和基因改变谱预测起源并指导位点特异性及靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although profiling of gene expression and gene alterations by next-generation sequencing (NGS) to predict the primary tumor site and guide molecularly targeted therapy might be expected to improve clinical outcomes for cancer of unknown primary site (CUP), to our knowledge, no clinical trial has previously evaluated this approach. OBJECTIVE: To assess the clinical use of site-specific treatment, including molecularly targeted therapy based on NGS results, for patients with CUP. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 clinical trial was conducted at 19 institutions in Japan and enrolled 111 previously untreated patients with the unfavorable subset of CUP between March 2015 and January 2018, with 97 patients being included in the efficacy analysis. Eligibility criteria included a diagnosis of unfavorable CUP after mandatory examinations, including pathological evaluation by immunohistochemistry, chest-abdomen-pelvis computed tomography scans, and a positron emission tomography scan. INTERVENTIONS: RNA and DNA sequencing for selected genes was performed simultaneously to evaluate gene expression and gene alterations, respectively. A newly established algorithm was applied to predict tumor origin based on these data. Patients received site-specific therapy, including molecularly targeted therapy, according to the predicted site and detected gene alterations. MAIN OUTCOMES AND MEASURES: The primary end point was 1-year survival probability. Secondary end points included progression-free survival (PFS), overall survival (OS), objective response rate, safety, efficacy according to predicted site, and frequency of gene alterations. RESULTS: Of 97 participants, 49 (50.5%) were women and the median (range) age was 64 (21-81) years. The cancer types most commonly predicted were lung (21 [21%]), liver (15 [15%]), kidney (15 [15%]), and colorectal (12 [12%]) cancer. The most frequent gene alterations were in TP53 (45 [46.4%]), KRAS (19 [19.6%]), and CDKN2A (18 [18.6%]). The 1-year survival probability, median OS, and median PFS were 53.1% (95% CI, 42.6%-62.5%), 13.7 months (95% CI, 9.3-19.7 months), and 5.2 months (95% CI, 3.3-7.1 months), respectively. Targetable EGFR mutations in tumor specimens were detected in 5 patients with predicted non-small-cell lung cancer (5.2%), 4 of whom were treated with afatinib; 2 of these patients achieved a durable PFS of longer than 6 months. CONCLUSIONS AND RELEVANCE: This study's findings suggest that site-specific treatment, including molecularly targeted therapy based on profiling gene expression and gene alterations by NGS, can contribute to treating patients with the unfavorable subset of CUP. TRIAL REGISTRATION: UMIN Identifier: UMIN000016794.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hayashi H, Takiguchi Y, Minami H, et al. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol. 2020. PMID: 33057591. doi:10.1001/jamaoncol.2020.4643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。